Gapping up
In reaction to strong earnings/guidance: SRT +15.7%, AMAT +8.6%, ICON+8.1%, AHS +7%, ANET +6.6%, HRTX +6.4%, AMBC +4.1%, INWK +4.1%, STS+4%, (thinly traded), BJRI +3.4%, BJRI +3.4%, COMM +2.5%, EPE +1.5%,AUY +1.5%, PEG +0.7%, .
M&A news: YHOO +2.8% (announces formed a Strategic Review Committee of independent directors to lead this effort, with the assistance and support of management)
Other news: NEOT +20.7% ( CEO and Chairman George Mahaffey resigns, effective immediately; also announced it is evaluating a path forward with a modified formulation of its lead asset LIPO-202), NVLS +3.3% ( announces FDA fast track designation for N91115 in patients with cystic fibrosis), ASML+1.5% (may be in symp with QCOM), QCOM +1.1% (Co and Lenovo (LNVGY) sign 3G/4G China patent license agreement), ARMH +0.9% (may be in symp with QCOM), .
Analyst comments: CTRP +1.3% (upgraded to Buy from Underperform at Credit Agricole)
In reaction to strong earnings/guidance: SRT +15.7%, AMAT +8.6%, ICON+8.1%, AHS +7%, ANET +6.6%, HRTX +6.4%, AMBC +4.1%, INWK +4.1%, STS+4%, (thinly traded), BJRI +3.4%, BJRI +3.4%, COMM +2.5%, EPE +1.5%,AUY +1.5%, PEG +0.7%, .
M&A news: YHOO +2.8% (announces formed a Strategic Review Committee of independent directors to lead this effort, with the assistance and support of management)
Other news: NEOT +20.7% ( CEO and Chairman George Mahaffey resigns, effective immediately; also announced it is evaluating a path forward with a modified formulation of its lead asset LIPO-202), NVLS +3.3% ( announces FDA fast track designation for N91115 in patients with cystic fibrosis), ASML+1.5% (may be in symp with QCOM), QCOM +1.1% (Co and Lenovo (LNVGY) sign 3G/4G China patent license agreement), ARMH +0.9% (may be in symp with QCOM), .
Analyst comments: CTRP +1.3% (upgraded to Buy from Underperform at Credit Agricole)